Background: We evaluated the usefulness of in vitro tumor culture system using a specialized collagen gel matrix (CGM assay) as a chemosensitivity test.
Patients And Methods: Chemosensitivity results of CGM assay were compared with other in vivo and in vitro assays on an implantable murine bladder tumor cell line (MBT-2). In addition we investigated the possibility of the clinical use of CGM assay using clinical specimens obtained from urogenital malignant tumor patients by comparing the result with that of the other chemosensitivity test, SDI testing using single cells (conventional SDI test). Methods of CGM assay were as follows. Tumor tissues on the collagen gel matrices were incubated under the existence of anticancer drugs following 4 days preculture. Drug sensitivities were evaluated by counting the number of viable cells adjusted to the tumor weight.
Results: Inhibition rates in MBT-2 were high in the order of mitomycin C, cisdiamminedichloroplatinum (II), (2"R)-4'-0-tetrahydropyranyl adriamycin. Four of 6 anticancer drugs were decided as chemosensitive drugs. These results corresponded to the results of the antitumor effects on subcutaneously transplanted MBT-2 in vivo, moreover was correlated well with those of the conventional SDI test. Twenty of 22 cases, including 11 of 13 bladder cancer cases, 1 of 3 renal cancer cases, 2 of 3 testicular cancer cases and 1 of 1 adrenal cortical cancer cases, were evaluable in the clinical study of the CGM assay. Corresponding rates between the results of the CGM assay and those of the conventional SDI test performed simultaneously in 12 cases were excellent for each anticancer drug.
Conclusion: This CGM assay can serve as an effective tool for chemosensitivity testing because of its convenience and high evaluable rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5980/jpnjurol1989.87.740 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of the initiation of isCGM soon after type 1 diabetes mellitus diagnosis in adults on glycemic indices and fear of hypoglycemia: a randomized controlled trial.
Front Endocrinol (Lausanne)
January 2025
Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland.
Background: Continuous glucose monitoring (CGM) improves glycemic control and quality of life. Data on glycemic indices and fear of hypoglycemia (FoH) in newly diagnosed T1DM patients are limited.
Aim: To assess the impact of initiating intermittently scanned CGM (isCGM) within 1-6 months of diagnosis on glycemic control and FoH in adults with T1DM.
Continuous Glucose Monitoring vs Fingerstick Monitoring for Hemoglobin A Control in Veterans.
Fed Pract
November 2024
Veterans Affairs Sioux Falls Health Care System, South Dakota.
Background: Patients with diabetes have traditionally been required to use fingerstick testing to self-monitor their glucose levels. However, continuous glucose monitors (CGMs) collect glucose readings throughout the day and display daily trends, which allow clinicians to individualize treatment to achieve hemoglobin A (HbA) goals and simplify medication regimens. While studies have shown that CGMs improve HbA levels compared to fingerstick testing, this research has focused on type 1 diabetes and excluded veterans and patients on insulin therapy.
View Article and Find Full Text PDFAccuracy of Freestyle Libre continuous glucose monitoring system in critically ill patients after cardiac surgery.
J Cardiothorac Surg
January 2025
Department of Cardiovascular Surgery, The first Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Background: Hyperglycemia is an independent risk factor for perioperative complications and mortality after cardiac surgery. Freestyle Libre Continuous glucose monitor (CGM) is an interstitial glucose monitoring system, which has been proven to be stable and accurate in various disease.
Materials And Methods: 86 patients with hyperglycemia after cardiac surgery between October 2021 and October 2022 in the cardiovascular ICU, were enrolled in this study.
Co-delivery of curcumin-resveratrol-carnosic acid complex promotes neurogenesis and cognitive recovery in a rodent model of repeated mild traumatic brain injury.
Biomed Pharmacother
January 2025
Centre for Neuroscience, Department of Biotechnology, Cochin University of Science and Technology, Kerala, India; Centre of Excellence in Neurodegeneration and Brain Health (CENABH), Kochi, Kerala, India. Electronic address:
Repeated traumatic brain injury has grown in importance as sports-related injuries have increased. Repetitive mild TBI (rmTBI) increases the risk of developing neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, as well as chronic comorbidities like PTSD, depression, substance abuse and neuroendocrine functions. However, no effective therapeutic strategies have been reported for the effective management of TBI.
View Article and Find Full Text PDFAddition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.
J Manag Care Spec Pharm
January 2025
Abbott Diabetes Care, Mississauga, Ontario, Canada.
Background: Both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and continuous glucose monitoring (CGM) have been shown to improve glycated hemoglobin A1c (A1c) levels among patients with type 2 diabetes mellitus (T2DM). Recently, a US real-world study found statistically significant improvements in A1c levels among patients using GLP-1 RA and a CGM device, compared with a matched cohort receiving only GLP-1 RA.
Objectives: To assess the cost-effectiveness from a US payer perspective of initiating CGM (FreeStyle Libre Systems) in people living with T2DM using a GLP-1 RA therapy, compared with GLP-1 RA alone.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!